Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe

BACKGROUND: Apixaban (ELIQUIS(®)) is a direct oral anticoagulant authorised for multiple indications in the European Economic Area (EEA). Additional risk minimisation measures (aRMMs) to address the risk of bleeding include educational materials comprising a Prescriber Guide and Patient Alert Card....

Descripción completa

Detalles Bibliográficos
Autores principales: Mayall, Steve, Kahlon, Randip, Al-Dakkak, Imad, Shen, Sophie W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979585/
https://www.ncbi.nlm.nih.gov/pubmed/33660230
http://dx.doi.org/10.1007/s40290-021-00380-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979585/
https://www.ncbi.nlm.nih.gov/pubmed/33660230
http://dx.doi.org/10.1007/s40290-021-00380-1

Ejemplares similares